Dynavax Technologies (NASDAQ:DVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Dynavax Technologies (NASDAQ:DVAX) had its price target lifted by analysts at HC Wainwright from $29.00 to $31.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 148.40% from the stock’s previous close.

Dynavax Technologies Price Performance

DVAX stock opened at $12.48 on Tuesday. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $14.41. The business’s 50 day simple moving average is $12.77 and its 200 day simple moving average is $11.66. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.64 billion, a PE ratio of 96.01 and a beta of 1.34.

Institutional Trading of Dynavax Technologies

A number of hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock valued at $27,830,000 after buying an additional 53,600 shares during the last quarter. Great Point Partners LLC grew its position in shares of Dynavax Technologies by 87.7% in the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after purchasing an additional 1,109,080 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Dynavax Technologies in the second quarter valued at approximately $17,615,000. Mizuho Markets Americas LLC increased its stake in shares of Dynavax Technologies by 17.4% during the third quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after purchasing an additional 204,475 shares during the period. Finally, Bank of Montreal Can lifted its holdings in Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after purchasing an additional 82,449 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.